A Phase 2 Study to Evaluate the Safety and Efficacy of Pacritinib in Relapsed or Refractory Waldenström Macroglobulinemia

This study is being done to examine the safety and effectiveness of pacritinib as a possible treatment for participants with Waldenström macroglobulinemia (WM). The name of the study drug involved in this study is: -Pacritinib (a type of kinase inhibitor)

NCT Number	NCT06986174
Lead Sponsor	Shayna Sarosiek, MD Collaborators: Sobi, Inc.
Conditions	Waldenström Macroglobulinemia, Lymphoplasmacytic Lymphoma, B-Cell Lymphoproliferative Disorder, Indolent Lymphoma
Enrollment	30 participants
Start Date	2025-11-21
Primary Completion	2028-10-01 (estimated)
Study Completion	2032-10-01 (estimated)
Updated on ClinicalTrials.gov	2025-12-05